Coya Therapeutics (NASDAQ:COYA) Given “Buy” Rating at Chardan Capital

Chardan Capital restated their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research note issued to investors on Wednesday morning, Benzinga reports. The firm currently has a $14.00 price target on the stock.

Separately, HC Wainwright started coverage on Coya Therapeutics in a report on Monday, September 16th. They issued a “buy” rating and a $18.00 price target on the stock.

Coya Therapeutics Stock Down 9.7 %

Shares of NASDAQ COYA opened at $6.66 on Wednesday. Coya Therapeutics has a 12-month low of $4.40 and a 12-month high of $10.69. The firm’s 50-day simple moving average is $6.87 and its 200 day simple moving average is $7.09. The company has a market cap of $97.28 million, a price-to-earnings ratio of -7.83 and a beta of 0.58.

Coya Therapeutics (NASDAQ:COYA) last announced its earnings results on Monday, August 12th. The company reported ($0.19) earnings per share (EPS) for the quarter. The firm had revenue of $3.43 million for the quarter. On average, equities analysts expect that Coya Therapeutics will post -1.27 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in Coya Therapeutics by 772.3% in the first quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock valued at $8,407,000 after buying an additional 750,338 shares during the period. GHP Investment Advisors Inc. bought a new position in Coya Therapeutics during the 3rd quarter worth approximately $169,000. Renaissance Technologies LLC acquired a new position in Coya Therapeutics during the second quarter valued at approximately $101,000. Finally, Gilbert & Cook Inc. bought a new stake in Coya Therapeutics in the second quarter valued at approximately $61,000. Institutional investors and hedge funds own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.